In the last week, the market has stayed flat, but it is up 26% over the past year with earnings forecast to grow by 16% annually. Investing in penny stocks — though somewhat of an outdated term — still presents opportunities for growth, particularly in smaller or newer companies. By focusing on those with strong financial health and potential for future growth, investors can find intriguing prospects that may offer both stability and upside.

Here we highlight a subset of our preferred stocks from the screener.

Veru (VERU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Veru Inc. is a late clinical stage biopharmaceutical company that develops medicines for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS), with a market cap of $36.11 million.

Operations: Veru Inc. has not reported any revenue segments.

Market Cap: $36.11M

Veru Inc., a pre-revenue biopharmaceutical company with a market cap of US$36.11 million, is navigating the clinical stage landscape with its novel therapies. The recent clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU study highlights Veru's strategic collaborations aimed at advancing enobosarm for obesity treatment. Despite its unprofitability, Veru has reduced losses over the past five years and maintains sufficient cash runway exceeding one year. However, the stock remains highly volatile and earnings are forecasted to decline in the near term, presenting both opportunities and challenges typical of penny stocks in this sector.

Health Catalyst (HCAT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Health Catalyst, Inc. offers data and analytics technology and services to healthcare organizations in the United States with a market cap of $98.28 million.

Operations: The company's revenue is derived from two main segments: Technology, contributing $206.26 million, and Professional Services, generating $96.22 million.

Market Cap: $98.28M

Health Catalyst, Inc., with a market cap of US$98.28 million, is navigating financial challenges typical of penny stocks. The company's revenue streams from Technology and Professional Services segments are substantial but have declined recently. Despite having sufficient cash runway for over three years and satisfactory net debt to equity ratio of 32.2%, Health Catalyst remains unprofitable with no forecasted profitability in the next three years. Recent strategic initiatives include leadership changes and workforce reductions under Project Nexus to streamline operations. The stock's volatility reflects these dynamics, alongside efforts to stabilize its financial structure amidst ongoing losses and impairments.

trivago (TRVG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: trivago N.V., along with its subsidiaries, operates a hotel and accommodation search platform across various countries including the United States, Germany, and Japan, with a market cap of approximately $290.58 million.

Operations: The company's revenue is derived from three primary geographical segments: Developed Europe at €230.45 million, the Americas with €213.09 million, and the Rest of World contributing €109.57 million.

Market Cap: $290.58M

trivago N.V., with a market cap of approximately $290.58 million, has recently achieved profitability, marking a significant milestone in its financial trajectory. The company's short-term assets (€233 million) comfortably cover both its short-term (€122 million) and long-term liabilities (€46.3 million), highlighting solid liquidity management. Despite recent insider selling, trivago's debt-free status and stable weekly volatility (8%) are positive indicators for investors cautious about risk in penny stocks. The company is focused on strategic growth, as evidenced by a €20 million share buyback program and reaffirmed guidance for double-digit revenue growth in 2026 amidst an expanding leadership team.

Taking Advantage

• Get an in-depth perspective on all 331 US Penny Stocks by using our screener here.
• Interested In Other Possibilities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.